Skip to main content

Table 4 Subgroup analysis according to PET timing and parameters

From: Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis

Outcomes

PET timing

PET parameter

Studies (n)

Pooled hazard ratios

95% confidence interval

I2 (%)

P for subgroup difference

Disease-free survival

Interim

%ΔSUVmax

9

0.20

0.13–0.31

0

0.8539

  

SUVmax

1

0.24

0.07–0.82

NA

 
  

CMR

2

0.31

0.07–1.37

32

 
 

Post-treatment

%ΔSUVmax

2

0.16

0.05–0.48

0

0.5821

  

%ΔSUVpeak

1

0.16

0.02–1.28

NA

 
  

%ΔMTV

1

0.39

0.19–0.79

NA

 
  

ΔSUVmax

2

0.38

0.19–0.78

0

 
  

CMR

3

0.25

0.12–0.50

0

 

Overall survival

Interim

%ΔSUVmax

3

0.20

0.09–0.44

0

0.7303

  

CMR

1

0.34

0.02–6.64

NA

 
 

Post-treatment

SUVmax

1

0.30

0.11–0.81

NA

0.7373

  

CMR

2

0.24

0.10–0.59

0

 
  1. CMR complete response, MTV metabolic tumour volume, NA not applicable, SUV standardised uptake value